Denise Dingle, MD
Family Medicine · Smithville, TNNPI 1518974732
Payments from drug & device makers
Across 100 payments — averaging $17.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$318
- AbbVie$307
- Pfizer$147
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$123
- Novo Nordisk$101
- Otsuka America Pharmaceutical, Inc.$96
- plus $608 from 20 others
What the payments were for
- Food & beverage$1,700100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 20 | $318 |
| AbbVie(2 entities) | 17 | $307 |
| Pfizer | 7 | $147 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $123 |
| Novo Nordisk | 7 | $101 |
| Otsuka America Pharmaceutical, Inc. | 6 | $96 |
| Merck | 6 | $82 |
| Bayer | 4 | $65 |
| Astellas Pharma US Inc | 3 | $61 |
| CMP Pharma, Inc. | 4 | $57 |
| Boehringer Ingelheim | 2 | $49 |
| Exact Sciences | 2 | $45 |
| Lilly USA, LLC | 3 | $44 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Vertex | 1 | $23 |
| Novartis | 1 | $17 |
| Lundbeck LLC | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Verona Pharma, Inc. | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Insulet Corporation | 1 | $12 |
| Amgen | 1 | $12 |
| Eisai Inc. | 1 | $11 |
| Athena Bioscience, LLC | 1 | $9 |
How this compares
$1,700 in reported general payments places this provider in the 65th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 134 | $134,097 |
| EliquisApixaban | 157 | $66,088 |
| MounjaroTirzepatide | 48 | $49,461 |
| JanuviaSitagliptin Phosphate | 47 | $46,666 |
| VraylarCariprazine Hcl | 28 | $41,547 |
| KerendiaFinerenone | 29 | $37,053 |
| JardianceEmpagliflozin | 67 | $32,531 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $31,395 |
| FarxigaDapagliflozin Propanediol | 37 | $30,528 |
| MyrbetriqMirabegron | 37 | $27,364 |
| LinzessLinaclotide | 32 | $25,489 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 30 | $19,122 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $14,308 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $14,252 |
| RybelsusSemaglutide | 12 | $13,199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $101 | $147,296146 claims |
| AbbVieVraylar, Linzess | $307 | $67,03660 claims |
| PfizerEliquis | $147 | $66,088157 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat | $49 | $57,335108 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $318 | $56,023100 claims |
| Lilly USA, LLCMounjaro | $44 | $49,46148 claims |
| MerckJanuvia | $82 | $46,66647 claims |
| BayerKerendia | $65 | $37,05329 claims |
| Astellas Pharma US IncMyrbetriq | $61 | $27,36437 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Smithville
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
- Marcus LeeTullahoma$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.